Suramin is a synthetic polysulfonated naphthylurea first made by Bayer around 1916-1920. For a century it has been used to treat early-stage African sleeping sickness (trypanosomiasis) and river blindness, and it sits on the WHO Model List of Essential Medicines. More recently it is studied as an antipurinergic agent that blocks extracellular ATP signalling.

Technical Specification · Compound Monograph

Suramin (antipurinergic therapy): the century-old drug now studied for blocking extracellular ATP signalling

Q: What is antipurinergic therapy?

Antipurinergic therapy (APT) is an experimental research idea in which a drug such as suramin blocks purinergic signalling - the messaging cells perform using extracellular ATP and related purines through P2X and P2Y receptors. The cell danger response hypothesis proposes that persistent purinergic danger signalling can keep cells locked in a defensive metabolic state. APT is research-stage and not an approved treatment for these uses.

Q: Is suramin an approved treatment for autism or chronic disease?

No. Suramin's only long-standing approved uses are antiparasitic (sleeping sickness, river blindness). Its use as antipurinergic therapy - including a small 2017 autism proof-of-concept trial by Robert Naviaux's group - is early experimental research, not an established or approved treatment. Suramin also carries meaningful toxicity, and unregulated claims about it (for example pine-needle or self-dosing myths) are not supported by evidence. Nothing here is medical advice.

Document — Specification Sheet

Subject: Suramin — antipurinergic agent (research use)
Class: Synthetic polysulfonated naphthylurea (small molecule)
Approved use: Antiparasitic — early-stage African trypanosomiasis; onchocerciasis
Under study: Purinergic (P2) receptor blockade — cell danger response hypothesis
Assignee: Panacea Bio Chem Ltd — research by Bogdan Dicoias, Scientist
Status: Descriptive / educational — experimental, not established for these uses
Revision: 2026-07-05 · Rev. 2

A research vial held in a chemistry laboratory illustrating suramin and antipurinergic therapy research — a Panacea Bio Chem page by Bogdan Dicoias — FIG. 1 A research vial in a working chemistry laboratory — illustrating the study of **suramin** and **antipurinergic therapy** at Panacea Bio Chem, Bogdan Dicoias. (Image is illustrative, not a suramin sample.)

Abstract

Suramin is a synthetic polysulfonated naphthylurea that has been in medicine for a century — a treatment for early-stage African sleeping sickness (trypanosomiasis)¹ and river blindness, and a fixture on the WHO Model List of Essential Medicines². Its large, heavily negatively charged molecule interacts with a wide range of proteins — including the P2 purinergic receptors³ that cells use to read extracellular ATP. That property has made it the reference tool of antipurinergic therapy (APT), an experimental research idea linked to the cell danger response hypothesis⁴. This page explains the science in plain language and states plainly that APT is early, contested and not an established treatment. Nothing here is medical advice.

1.0 Field of the disclosure — what suramin is

[0001] Imagine a drug older than antibiotics that is still on the essential-medicines list, and that scientists keep rediscovering for reasons its inventors never imagined. That is suramin. Chemically it is a big, symmetrical molecule carrying six sulfonate groups, which make it strongly water-soluble and strongly negatively charged. It does not slip easily into cells or across the blood–brain barrier; it is given by slow intravenous injection and lingers in the body for weeks.

[0002] For a hundred years its job was to kill parasites. It clears the trypanosomes of early-stage African sleeping sickness and is used against the worm behind river blindness (onchocerciasis)¹. What is new is not the molecule but the question being asked of it: because that dense negative charge lets suramin sit on many signalling proteins at once, researchers now study it as a way to quiet purinergic signalling — the conversation cells hold using ATP outside the cell.

2.0 Background — a molecule that was once a state secret

[0003] Suramin was synthesised at Bayer around 1916–1920 by chemists Oskar Dressel, Richard Kothe and Bernhard Heymann, from dye chemistry that grew out of the trypan-red and trypan-blue work of Paul Ehrlich. Bayer marketed it as "Bayer 205" and later "Germanin," and — here is the STORY — kept its exact structure a guarded secret for years, treating the formula as a strategic national asset in the colonial scramble for tropical medicine⁵.

[0004] The secret did not hold. At the Institut Pasteur in Paris, the chemist Ernest Fourneau and his team reverse-engineered the compound and, in 1924, published their own synthesis — sold as "Fourneau 309" — breaking Bayer's monopoly⁵. A drug whose recipe two nations fought to keep or crack is, a century later, an off-patent essential medicine anyone can read about. There is a quiet lesson in that for anyone who builds proprietary methods: the science outlives the secrecy — the edge is in doing it, repeatably.

Positioning note Suramin is a real, approved antiparasitic medicine with a well-documented profile for that use under medical supervision. Everything beyond that — the antipurinergic ideas below — is research, and is described here as research.

3.0 Principle — antipurinergic therapy and the cell danger response

The signal: extracellular ATP as a danger flare

[0005] Inside a cell, ATP is the fuel of life. Outside the cell, ATP means something very different. When a cell is stressed, infected or injured, it leaks or releases ATP into the space around it, where neighbouring cells detect it through purinergic receptors — the P2X ion channels and P2Y G-protein receptors³. Extracellular ATP is, in effect, a chemical flare: a broadcast that says "danger here." This purinergic signalling shapes inflammation, pain, immune activation and how cells route their metabolism.

The hypothesis: a cell stuck in defence mode

[0006] The cell danger response (CDR), articulated by Robert Naviaux at UC San Diego, proposes that after a threat some cells fail to switch the alarm off. Persistent extracellular-ATP signalling could keep them in a defensive, low-cooperation state — a plausible common thread the hypothesis links to several chronic conditions⁴. Antipurinergic therapy is the experimental move that follows: transiently block the ATP signal — with suramin as the classic, broad P2-receptor antagonist — to let the cell stand down and metabolism re-normalise. It is an elegant idea. It is also, at this stage, a hypothesis under test, not a settled mechanism of disease.

Ribbon rendering of a membrane receptor structure representing a purinergic P2 receptor — the antipurinergic therapy target that suramin blocks, Panacea Bio Chem, Bogdan Dicoias — FIG. 2 A ribbon rendering of a membrane receptor, of the general kind cells use to read extracellular ATP. **Purinergic P2 receptors** are the target that antipurinergic therapy — and **suramin** — acts on. Panacea Bio Chem, Bogdan Dicoias. (Illustrative structure.)

4.0 Why it matters — and why to stay careful

[0007] If the cell danger response idea is even partly right, a well-timed antipurinergic pulse would be a genuinely new lever on chronic inflammatory and neurodevelopmental biology — pharmacology aimed at a signalling state rather than a single molecule. The most cited human probe is a small 2017 phase I/II trial from Naviaux's group testing a single low-dose suramin infusion in autism spectrum disorder, which reported transient behavioural changes in a handful of participants⁶.

[0008] That trial is best read as a proof-of-concept, not a result to build hope on. It was tiny, brief and exploratory. Suramin itself carries real toxicity with repeated dosing — effects on the adrenal glands, nerves, kidneys and clotting are documented from its antiparasitic and 1990s oncology use. And the compound has attracted a fog of online misinformation (pine-needle "sources," self-dosing schemes) that has no scientific basis. This is a topic where the honest scientific posture is curiosity with the brakes on: real mechanism, real questions, and results that are not established for any chronic-disease use.

Status Antipurinergic therapy with suramin is experimental. It is not an approved treatment for autism, ageing, cancer or any chronic condition, and it is not something to self-administer. Claims of at-home or "natural" suramin are not supported by evidence.

5.0 Panacea Bio Chem's angle

[0009] Panacea Bio Chem researches the purinergic sphere — the chemistry of extracellular ATP signalling and antipurinergic modulation — as an ongoing programme led by Bogdan Dicoias, the scientist behind the group's proprietary methods. As with its lyophilization and formulation technologies, Panacea's stance here is method-first: the value is in how a fragile, highly charged molecule is handled, characterised and studied.

[0010] The disciplines are adjacent to Panacea's existing work: handling degradation-prone actives is exactly the problem behind RedoxVault — the vault that isolates a molecule from oxidative attack → and OxyDeplete, which strips the oxygen that quietly degrades actives →, while stabilising them as a solid dose is the domain of Cryolapse, the gentle cryogenic freeze-dry → and TgShift, which lifts the glass-transition ceiling →.

6.0 Potential application fields

[0011] Where might careful purinergic research "hit where it hurts most"? Read as directions for study, not as claims:

Chronic inflammatory and neuro-immune conditions — where a persistent danger signal, if real, would be the highest-value target to interrupt.
Neurodevelopmental research — the most-discussed and most-scrutinised frontier; the one that most needs rigorous, adequately powered trials rather than hope.
Chronic pain and neuropathic signalling — P2X receptors are well-established in pain pathways, an area with deep unmet need.
Fibrosis and tissue-repair biology — where extracellular-ATP signalling steers how tissue rebuilds after injury.
Formulation & delivery science — a large, charged molecule that resists cells and the blood–brain barrier is a hard delivery problem, and a natural fit for Panacea's handling and stabilisation methods.

[0012] Each of these is a question, offered as inspiration for disciplined research and trials — not a destination reached.

7.0 Suramin at a glance

Chemical class	Synthetic polysulfonated naphthylurea (six sulfonate groups)
First synthesised	c. 1916–1920, Bayer (Dressel, Kothe, Heymann); "Bayer 205" / "Germanin"
Approved indications	Early-stage African trypanosomiasis; onchocerciasis (river blindness)
Route	Slow intravenous infusion (poor cell / blood–brain-barrier entry)
Molecular targets	Broad — including P2X / P2Y purinergic receptors, plus many enzymes
Research interest	Antipurinergic therapy (APT); cell danger response hypothesis
Status of APT use	Experimental — not established for chronic disease
Regulatory listing	WHO Model List of Essential Medicines (antiparasitic use)

Frequently asked

What is suramin?
A synthetic polysulfonated naphthylurea made by Bayer around 1916–1920. For a century it has treated early-stage African sleeping sickness and river blindness, and it is on the WHO essential-medicines list. Its dense negative charge also lets it block P2 purinergic receptors, which is why it is now studied as an antipurinergic agent.

What is antipurinergic therapy?
An experimental research idea in which a drug like suramin blocks purinergic signalling — the messaging cells do with extracellular ATP through P2X and P2Y receptors. The cell danger response hypothesis suggests some cells stay stuck in an ATP-driven alarm state; APT aims to interrupt it. It is research-stage.

Is suramin an approved treatment for autism or chronic disease?
No. Its only long-standing approved uses are antiparasitic. The antipurinergic work — including a small 2017 autism proof-of-concept trial — is experimental, not established or approved, and suramin carries real toxicity. "Natural" or self-dosed suramin claims are not supported by evidence. Nothing here is medical advice.

Trending in the field

References & further reading

Suramin — history, pharmacology and antiparasitic use. Wikipedia.
WHO Model List of Essential Medicines. Wikipedia.
Purinergic signalling and P2 receptors (P2X / P2Y). Wikipedia.
Naviaux RK. Metabolic features of the cell danger response. PubMed (2014).
Suramin's discovery, "Bayer 205"/Germanin and Fourneau's 1924 synthesis. Wikipedia — History.
Naviaux RK, et al. Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial. PubMed (2017).